Scotia Capital’s Phibro Animal Health PAHC Stock Holding History

Scotia Capital’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,603	Closed	-$227K	–	938
2025 Q3	$227K	Buy	+5,603	New	+$185K	﹤0.01%	819

Other funds holding PAHC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Scotia Capital's PAHC Position: Q4 2025 in Review

Scotia Capital sold out of Phibro Animal Health (PAHC) in Q4 2025, closing a stake of 5,603 shares — an estimated $227K sold.

Scotia Capital first reported a position in PAHC in Q3 2025 and held it in 1 quarter. The position peaked at $227K in Q3 2025. 227 funds tracked by Wall St. Rank hold PAHC as of Q4 2025.

Scotia Capital reported no remaining Phibro Animal Health position as of Q4 2025 after selling out during the quarter.
Scotia Capital sold 5,603 Phibro Animal Health shares in Q4 2025, an estimated $227K.
Scotia Capital first reported a position in Phibro Animal Health in Q3 2025 and held it in 1 quarter.
Scotia Capital's Phibro Animal Health position peaked at $227K in Q3 2025.
227 funds tracked by Wall St. Rank held Phibro Animal Health as of Q4 2025.

Based on Scotia Capital's 13F filing for Q4 2025, filed 12 Feb 2026.